GSK 2241658A

N/A

Report date: 2023/04/17 20:00:35

Base Information

Drug NameGSK 2241658A
Drug Alias NameGSK Biologicals' 2241658A Antigen-Specific Cancer ImmunotherapeuticGSK 2241658A Antigen-Specific Cancer ImmunotherapeuticNY-ESO-1 Antigen Specific Cancer ImmunotherapeuticGSK-2241658AGSK-2241658A ASCI +[6] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPsoriasisMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsItalyAustralia +[8] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsPsoriasisMelanoma

Other Information

ATC CodeN/A
Related LinksN/A